DK2310413T3 - Kamelidafledte antigenbindende polypeptider - Google Patents
Kamelidafledte antigenbindende polypeptider Download PDFInfo
- Publication number
- DK2310413T3 DK2310413T3 DK09772912.3T DK09772912T DK2310413T3 DK 2310413 T3 DK2310413 T3 DK 2310413T3 DK 09772912 T DK09772912 T DK 09772912T DK 2310413 T3 DK2310413 T3 DK 2310413T3
- Authority
- DK
- Denmark
- Prior art keywords
- domain
- human
- antigen
- binding polypeptide
- antibodies
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims description 341
- 108091007433 antigens Proteins 0.000 title claims description 341
- 102000036639 antigens Human genes 0.000 title claims description 341
- 230000027455 binding Effects 0.000 title claims description 230
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 197
- 229920001184 polypeptide Polymers 0.000 title claims description 196
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 196
- 241000282414 Homo sapiens Species 0.000 claims description 363
- 210000004602 germ cell Anatomy 0.000 claims description 161
- 241000282832 Camelidae Species 0.000 claims description 115
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 91
- 241000282842 Lama glama Species 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 88
- 241000282836 Camelus dromedarius Species 0.000 claims description 79
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 77
- 210000004027 cell Anatomy 0.000 claims description 58
- 239000013604 expression vector Substances 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 44
- 241000894007 species Species 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 32
- 241001416177 Vicugna pacos Species 0.000 claims description 31
- 108091033319 polynucleotide Proteins 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 102000040430 polynucleotide Human genes 0.000 claims description 31
- 230000001225 therapeutic effect Effects 0.000 claims description 25
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 102
- 108090000623 proteins and genes Proteins 0.000 description 78
- 238000002649 immunization Methods 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 44
- 210000003719 b-lymphocyte Anatomy 0.000 description 38
- 239000013598 vector Substances 0.000 description 36
- 239000013615 primer Substances 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 31
- 238000004519 manufacturing process Methods 0.000 description 31
- 230000008569 process Effects 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 27
- 102000004127 Cytokines Human genes 0.000 description 26
- 125000000539 amino acid group Chemical group 0.000 description 26
- 238000013459 approach Methods 0.000 description 26
- 238000006467 substitution reaction Methods 0.000 description 26
- 108090000695 Cytokines Proteins 0.000 description 25
- 241000282838 Lama Species 0.000 description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 238000010367 cloning Methods 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 21
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 108090000193 Interleukin-1 beta Proteins 0.000 description 20
- 102000003777 Interleukin-1 beta Human genes 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 19
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 17
- 230000003321 amplification Effects 0.000 description 17
- 238000003199 nucleic acid amplification method Methods 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 16
- 230000000670 limiting effect Effects 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 15
- 108060003951 Immunoglobulin Proteins 0.000 description 14
- 102000018358 immunoglobulin Human genes 0.000 description 14
- 238000012216 screening Methods 0.000 description 14
- 108091093088 Amplicon Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 210000003563 lymphoid tissue Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 10
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 10
- 241000282412 Homo Species 0.000 description 10
- 230000003042 antagnostic effect Effects 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 9
- 238000000137 annealing Methods 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 108700005078 Synthetic Genes Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 102000043381 human DUSP5 Human genes 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 7
- 238000002823 phage display Methods 0.000 description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 6
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
- 108010090804 Streptavidin Proteins 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 238000000670 ligand binding assay Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 230000008570 general process Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 241001244729 Apalis Species 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000010187 selection method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 3
- 229960003669 carbenicillin Drugs 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012916 structural analysis Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000002424 x-ray crystallography Methods 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical class NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 2
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 230000010799 Receptor Interactions Effects 0.000 description 2
- 244000000188 Vaccinium ovalifolium Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000013357 binding ELISA Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- -1 for example cells Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 108010087904 neutravidin Proteins 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000002702 ribosome display Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HOSWPDPVFBCLSY-UHFFFAOYSA-N 2-azaniumyl-4-oxobutanoate Chemical compound OC(=O)C(N)CC=O HOSWPDPVFBCLSY-UHFFFAOYSA-N 0.000 description 1
- CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 101100082447 Arabidopsis thaliana PBL1 gene Proteins 0.000 description 1
- 101100082457 Arabidopsis thaliana PBL2 gene Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000771208 Buchanania arborescens Species 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- 241000282826 Camelus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101100203200 Danio rerio shha gene Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241001397104 Dima Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000702224 Enterobacteria phage M13 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 101100084627 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pcb-4 gene Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000161214 Pelates Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 description 1
- 101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000003016 alphascreen Methods 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000001314 canonical amino-acid group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000011037 discontinuous sequential dilution Methods 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (12)
1. Monoklonalt antigenbindende polypeptid omfattende et VH-domæne og et VL-domæne, hvori hver af de hypervariable sløjfer i både VH-domænet og VL-domænet opnås fra et VH- eller VL-domæne af en art i familien Camelidae, hvori hypervariabel sløjfe H1 og hypervariabel sløjfe H2 i VH-domænet hver udviser en forudsagt eller faktisk kanonisk foldestruktur, som er identisk med en kanonisk foldestruktur, som forekommer i humane antistoffer, og hvori hypervariabel sløjfe H1 og hypervariabel sløjfe H2 i VH-domænet danner en kombination af forudsagte eller faktiske kanoniske foldestrukturer, som er identiske med en kombination af kanoniske foldestrukturer som er kendt at forekomme i et humant kimlinje-VH-domæne.
2. Antigenbindende polypeptid ifølge krav 1 omfattende et VH-domæne, hvori VH-domænet udviser en sekvensidentitet på 80% eller mere, 85% eller mere, 90% eller mere, 95% eller mere, eller 97% eller mere med et eller flere humane VH-domæner på tværs af strukturområderne FR1, FR2, FR3 og FR4, og hvori VL-domænet udviser en sekvensidentitet på 80% eller mere, 85% eller mere, 90% eller mere, 95% eller mere, eller 97% eller mere med et eller flere humane VL-domæner på tværs af strukturområderne FR1, FR2, FR3 og FR4.
3. Antigenbindende polypeptid ifølge krav 1, som udviser en sekvensidentitet på 80% eller mere med et humant VH-domæne på tværs af strukturområderne FR1, FR2, FR3 og FR4, og hvori hypervariabel sløjfe H1 og hypervariabel sløjfe H2 danner en kombination af forudsagte eller faktiske kanoniske foldestrukturer, som er det samme som en kanonisk foldekombination, som er kendt at forekomme naturligt i samme humane VH-domænet.
4. Antigenbindende polypeptid ifølge ethvert af kravene 1 til 3, hvori hypervariabel sløjfe L1 og hypervariabel sløjfe L2 i VL-domænet hver er opnået fra et VH- eller VL-domæne af en art i familien Camelidae og hver udviser et forudsagt eller faktisk kanonisk foldestruktur, som er identisk med en kanonisk foldestruktur, som forekommer i humane antistoffer, og hvori hypervariabel sløjfe L1 og hypervariabel sløjfe L2 i VL-domænet danner en kombination af forudsagte eller faktiske kanoniske foldestrukturer, som er identiske med en kombination af kanoniske foldestrukturer, som er kendt at forekomme i et humant kimlinje-VL-domæne.
5. Antigenbindende polypeptid ifølge et hvilket som helst af de foregående krav, hvori arten i familien Camelidae er valgt fra gruppen bestående af kamel, lama, dromedar, vikunja, guanako og alpaka.
6. Antigenbindende polypeptid ifølge et hvilket som helst af de foregående krav, som er immunoreaktiv med eller specifikt binder til et target-antigen, nævnte target-antigen er et ikke-kamelidantigen, eller et humant antigen eller et viralt antigen eller et bakterielt antigen, eller en target af terapeutisk eller diagnostisk betydning.
7. Antigenbindende polypeptid ifølge et hvilket som helst af de foregående krav, som er et kimærisk polypeptid, der omfatter mindst et konstant domæne med en aminosyresekvens, der kodes af et humant immunglobulingen, eller en aminosyresekvens, som er mindst 90% identisk dermed, eller som omfatter den komplette konstante region af et humant antistof.
8. Antigenbindende polypeptid ifølge et hvilket som helst af de foregående krav, som er et antistof, Fab, Fab', F(ab')2, bispecifikke Fab', Fv-fragmenter, diabody, lineært antistof, et enkeltkædet variabelt fragment (scFv) eller multispecifikt antistof dannet fra antistoffragmenter.
9. Polynukleotidmolekyle, der koder for et antigenbindende polypeptid ifølge et hvilket som helst af kravene 1 til 8.
10. Ekspressionsvektor omfattende polynukleotidmolekylet ifølge krav 9 operativt koblet til regulatoriske sekvenser, som tillader ekspression af det antigenbindende polypeptid i en værtscelle eller et cellefrit ekspressionssystem.
11. Værtscelle eller cellefrit ekspressionssystem indeholdende ekspressionsvektoren ifølge krav 10.
12. Fremgangsmåde til at fremstille et rekombinant antigenbindende polypeptid, som omfatter dyrkning af værtscellen eller det cellefrie ekspressionssystem ifølge krav 11 under betingelser, som tillader ekspression af det antigenbindende polypeptid og udvinding af det udtrykte antigenbindende polypeptid.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7773008P | 2008-07-02 | 2008-07-02 | |
GB0812120A GB2461546B (en) | 2008-07-02 | 2008-07-02 | Antigen binding polypeptides |
US11016108P | 2008-10-31 | 2008-10-31 | |
PCT/IB2009/006329 WO2010001251A2 (en) | 2008-07-02 | 2009-07-02 | Antigen binding polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2310413T3 true DK2310413T3 (da) | 2017-06-06 |
Family
ID=39707916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09772912.3T DK2310413T3 (da) | 2008-07-02 | 2009-07-02 | Kamelidafledte antigenbindende polypeptider |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP2310413B1 (da) |
JP (1) | JP6216940B2 (da) |
CN (2) | CN102216328A (da) |
AU (1) | AU2009265278B2 (da) |
CA (1) | CA2728076C (da) |
DK (1) | DK2310413T3 (da) |
GB (1) | GB2461546B (da) |
WO (1) | WO2010001251A2 (da) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
KR101930964B1 (ko) | 2010-04-20 | 2018-12-19 | 젠맵 에이/에스 | 이종이량체 항체 fc-함유 단백질 및 그의 생산 방법 |
IL299365A (en) | 2010-05-27 | 2023-02-01 | Genmab As | Monoclonal antibodies against 2HER |
PL2621531T3 (pl) | 2010-09-27 | 2017-07-31 | Morphosys Ag | Przeciwciało anty-CD38 i lenalidomid lub bortezomib do leczenia szpiczaka mnogiego i NHL |
CN103764678A (zh) | 2010-11-03 | 2014-04-30 | 阿尔金-X公司 | c-Met抗体组合 |
CA2997473C (en) * | 2010-12-31 | 2023-10-03 | Bioatla, Llc | Comprehensive monoclonal antibody generation |
EP2686347B1 (en) * | 2011-03-16 | 2018-05-02 | argenx BVBA | Antibodies to cd70 |
CN103796678B (zh) | 2011-04-20 | 2018-02-27 | 健玛保 | 针对her2的双特异性抗体 |
AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
SI2771364T1 (sl) | 2011-10-27 | 2019-10-30 | Genmab As | Produkcija heterodimernih proteinov |
WO2013064700A2 (en) * | 2011-11-03 | 2013-05-10 | Argen-X B.V. | Chimeric polypeptides and methods of use |
GB2504139B (en) | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
CN104583238A (zh) * | 2012-08-31 | 2015-04-29 | 阿尔金-X有限公司 | 用于产生具有物种间、靶标内交叉反应性之抗体分子的方法 |
US10040870B2 (en) * | 2012-08-31 | 2018-08-07 | Argenx Bvba | Highly diverse combinatorial antibody libraries |
MY174813A (en) | 2013-03-15 | 2020-05-16 | Zymeworks Inc | Cytotoxic and anti-mitotic compounds, and methods of using the same |
EP3027650B1 (en) * | 2013-08-01 | 2021-01-13 | Université catholique de Louvain | Antibody binding a complex of human glycoprotein a repetitions predominant (garp) and latent tgf-beta-1 |
WO2015021080A2 (en) | 2013-08-05 | 2015-02-12 | Twist Bioscience Corporation | De novo synthesized gene libraries |
US10017559B2 (en) | 2013-11-04 | 2018-07-10 | INSERM (Institut National de la Santé et de la Recherche Médicale | Synthetic single domain antibody |
CN106255513B (zh) | 2013-12-27 | 2022-01-14 | 酵活有限公司 | 用于药物偶联物的含磺酰胺连接系统 |
US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
AU2015318556C1 (en) | 2014-09-17 | 2021-01-07 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
RU2609627C2 (ru) | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
EP3350314A4 (en) | 2015-09-18 | 2019-02-06 | Twist Bioscience Corporation | BANKS OF OLIGONUCLEIC ACID VARIANTS AND SYNTHESIS THEREOF |
KR20180058772A (ko) | 2015-09-22 | 2018-06-01 | 트위스트 바이오사이언스 코포레이션 | 핵산 합성을 위한 가요성 기판 |
GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
AU2017292184A1 (en) | 2016-07-08 | 2019-02-07 | Staten Biotechnology B.V. | Anti-Apoc3 antibodies and methods of use thereof |
GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
CN110248724B (zh) | 2016-09-21 | 2022-11-18 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
WO2018103093A1 (zh) * | 2016-12-09 | 2018-06-14 | 深圳华大基因研究院 | 骆驼科抗体可变区免疫组库构建的引物组合及应用 |
WO2018156792A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
KR20190141659A (ko) | 2017-04-21 | 2019-12-24 | 스태튼 바이오테크놀로지 비.브이. | 항-apoc3 항체 및 이의 사용 방법 |
GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
EP3638782A4 (en) | 2017-06-12 | 2021-03-17 | Twist Bioscience Corporation | SEALLESS NUCLEIC ACID ASSEMBLY METHODS |
CA3075505A1 (en) | 2017-09-11 | 2019-03-14 | Twist Bioscience Corporation | Gpcr binding proteins and synthesis thereof |
CA3079613A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
BR112020008514A2 (pt) | 2017-10-31 | 2020-10-20 | Staten Biotechnology B.V. | anticorpos anti-apoc3 e métodos de uso dos mesmos |
US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
IT201800000535A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. | |
GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
KR20210005070A (ko) | 2018-04-13 | 2021-01-13 | 아르제넥스 비브이비에이 | 갈랙틴-10 항체 |
GB2590196A (en) | 2018-05-18 | 2021-06-23 | Twist Bioscience Corp | Polynucleotides, reagents, and methods for nucleic acid hybridization |
CN109206511B (zh) * | 2018-09-13 | 2021-03-16 | 东南大学 | 能够特异结合HPVl6-E6蛋白的纳米抗体及其编码序列、制备方法和应用 |
UY38511A (es) | 2018-12-18 | 2020-07-31 | Argenx Bvba | Terapia de combinación cd70 |
WO2020176680A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
EP3930754A4 (en) * | 2019-02-27 | 2023-08-16 | Zhejiang Nanomab Technology Center Co. Ltd. | HIGH-THROUGHPUT SEQUENCE-BASED PROCEDURE FOR GENERATION OF CAMELID ANTIBODIES TO COVER WIDE EPITOPES WITH HIGH RESOLUTION |
WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
EP3987019A4 (en) | 2019-06-21 | 2023-04-19 | Twist Bioscience Corporation | BARCODE-BASED NUCLEIC ACID SEQUENCE ARRANGEMENT |
CN110642948B (zh) * | 2019-10-09 | 2021-06-29 | 达石药业(广东)有限公司 | B7-h3纳米抗体、其制备方法及用途 |
JPWO2021132596A1 (da) * | 2019-12-27 | 2021-07-01 | ||
GB202003444D0 (en) | 2020-03-10 | 2020-04-22 | argenx BV | Musk agonist antibody |
CN114591436B (zh) * | 2020-12-07 | 2022-12-02 | 生物岛实验室 | 胃蛋白酶原i的特异性抗体及其制备方法与应用 |
CA3218481A1 (en) | 2021-06-14 | 2022-12-22 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
CN118434440A (zh) | 2022-01-18 | 2024-08-02 | 阿根思有限公司 | Fab片段的雾化 |
WO2023139107A1 (en) | 2022-01-18 | 2023-07-27 | argenx BV | Galectin-10 antibodies |
GB202203269D0 (en) | 2022-03-09 | 2022-04-20 | Argenx Iip Bv | TGF-Beta antibodies |
CN117310163B (zh) * | 2023-11-23 | 2024-02-13 | 北京贝思泰生物科技有限公司 | 一种基于重组抗体的呼吸道合胞病毒检测方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2338791T3 (es) * | 1992-08-21 | 2010-05-12 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
GB9926084D0 (en) * | 1999-11-03 | 2000-01-12 | King S College London | Recombinant fusion molecules |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2002324973A1 (en) * | 2001-09-14 | 2003-04-01 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandandten Forschung E.V. | Immunoglobulin having particular framework scaffold and methods of making and using |
EP3415535B1 (en) * | 2005-05-20 | 2020-12-09 | Ablynx N.V. | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
US20070269442A1 (en) * | 2006-05-19 | 2007-11-22 | Robert J. Webber | Chimeric monoclonal antibody recognizing iNOS |
US8796429B2 (en) * | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
BRPI0718118A2 (pt) * | 2006-10-27 | 2017-05-30 | Lpath Inc | composições e métodos para ligação de sphingosine-1-fosfato |
WO2008070367A2 (en) * | 2006-11-01 | 2008-06-12 | Facet Biotech Corporation | Mammalian cell-based immunoglobulin display libraries |
US8455626B2 (en) * | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
-
2008
- 2008-07-02 GB GB0812120A patent/GB2461546B/en active Active
-
2009
- 2009-07-02 AU AU2009265278A patent/AU2009265278B2/en active Active
- 2009-07-02 DK DK09772912.3T patent/DK2310413T3/da active
- 2009-07-02 EP EP09772912.3A patent/EP2310413B1/en active Active
- 2009-07-02 EP EP15190638.5A patent/EP3061768A1/en not_active Withdrawn
- 2009-07-02 CA CA2728076A patent/CA2728076C/en active Active
- 2009-07-02 JP JP2011515664A patent/JP6216940B2/ja active Active
- 2009-07-02 CN CN2009801343928A patent/CN102216328A/zh active Pending
- 2009-07-02 CN CN201710747051.4A patent/CN107739405A/zh active Pending
- 2009-07-02 WO PCT/IB2009/006329 patent/WO2010001251A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
GB0812120D0 (en) | 2008-08-06 |
AU2009265278B2 (en) | 2015-03-19 |
CA2728076A1 (en) | 2010-01-07 |
WO2010001251A2 (en) | 2010-01-07 |
JP2011526493A (ja) | 2011-10-13 |
CA2728076C (en) | 2020-05-19 |
WO2010001251A3 (en) | 2010-03-11 |
CN102216328A (zh) | 2011-10-12 |
GB2461546B (en) | 2010-07-07 |
EP3061768A1 (en) | 2016-08-31 |
EP2310413B1 (en) | 2017-03-01 |
GB2461546A (en) | 2010-01-06 |
CN107739405A (zh) | 2018-02-27 |
AU2009265278A1 (en) | 2010-01-07 |
EP2310413A2 (en) | 2011-04-20 |
JP6216940B2 (ja) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2310413T3 (da) | Kamelidafledte antigenbindende polypeptider | |
US9221918B2 (en) | Antigen binding polypeptides | |
US9540437B2 (en) | Humanized antibodies | |
US20150191548A1 (en) | Antibodies comprising sequences from camelidae to highly conserved targets | |
JP2018064561A (ja) | ラクダ科動物由来の抗原結合ポリペプチド | |
WO2023161448A1 (en) | Human-like target-binding proteins |